健脾通络汤治疗脾胃虚弱型慢性萎缩性胃炎的效果研究

目的探讨健脾通络汤治疗脾胃虚弱型慢性萎缩性胃炎的临床疗效。方法根据随机数字表法,将2015年1月~2016年10月我院80例脾胃虚弱型慢性萎缩性胃炎患者分成对照组(西药治疗)和观察组(健脾通络汤),每组各40例,比较两组治疗的临床疗效、中医症候积分改善情况,以及不良反应。结果与对照组相比,观察组治疗的总有效率明显增高,差异有统计学意义(P<0.05);与对照组相比,观察组中医症候积分显著下降,差异有统计学意义(P<0.05);治疗期间两组都没有出现明显的不良反应。结论健脾通络汤治疗脾胃虚弱型慢性萎缩性胃炎的疗效显著,明显改善中医证候,具有较高治疗安全性,值得临床推广。     

和胃消疡汤经验方辨治肝胃不和型胃溃疡的临床研究

目的:探讨和胃消疡汤经验方辨治肝胃不和型胃溃疡的临床效果.方法:选取100例在我院就诊的肝胃不和型胃溃疡患者纳入研究,将其随机分为两组,对照组(50例)采用三联疗法治疗,观察组(50例)在此基础上行和胃消疡汤经验方辨证治疗,对比两组临床效果、中医症候积分和复发率.结果:观察组临床总有效率显著高于对照组(P<0.05),治疗后观察组各项中医症候积分均明显优于对照组(P<0.05),随访1年,观察组复发率明显低于对照组(P<0.05).结论:在常规三联疗法的基础上对肝胃不和型胃溃疡实施和胃消疡汤经验方辨证治疗效果显著,可改善症状,减少复发,可在临床上推广.     

胆囊炎方治疗慢性胆囊炎的临床研究

目的探讨胆囊炎方治疗慢性胆囊炎的临床效果。方法选取来我院进行治疗的慢性胆囊炎患者60例,将患者进行随机分组,分为观察组和对照组两组。对照组18例患者给与口服消炎利胆片进行治疗,观察组患者给与煎服胆囊炎方进行治疗。结果观察组患者的临床治疗总有效率为92.8%,显著高与对照组患者的77.8%,比较差异具有统计学意义(P<0.05)。B超影像学检查:观察组患者治疗后的总有效率为71.4%,对照组患者治疗后的总有效率为72.4%,比较差异不具有统计学意义(P>0.05)。观察组和对照组患者治疗后的中医症候积分较治疗前有显著改善,组内比较差异具有统计学意义(P<0.05);观察组患者治疗后的中医症候积分较对照组有显著改善,组间比较差异具有统计学意义(P>0.05)。结论胆囊炎方治疗慢性胆囊炎具有临床疗效显著,中医症候积分改善显著,不良反应较少等临床价值,值得在临床进行推广应用。     

健脾渗湿方联合化疗治疗结肠癌患者术后对免疫功能、远期预后的影响

目的 探讨健脾渗湿方联合化疗治疗结肠癌患者术后对免疫功能、远期预后的影响.方法 将2019年1月至2020年10月在本院行结肠癌根治术的87例结肠癌患者纳入研究,以随机数字表法分为治疗组(n=45)与对照组(n=42),对照组术后给予化疗治疗,治疗组在对照组基础上采取中药健脾渗湿方治疗,疗程结束后评估2组近期疗效、中医证候积分、免疫功能及生活质量.结果 治疗组近期治疗总有效率(88.89％)优于对照组(69.05％)(P<0.05);2组治疗前中医证候积分相比无明显差异(P>0.05),2组治疗后中医证候积分低于治疗前,治疗组低于对照组(P<0.05);2组治疗前免疫功能指标(CD3+、CD4+、CD8+、CD4+/CD8+)比较差异无统计学意义(P>0.05),治疗后,治疗组CD3+、CD4+、CD4+/CD8+水平比较治疗前提高,CD8+水平较治疗前降低(P<0.05),对照组治疗前后CD3+、CD4+、CD8+、CD4+/CD8+水平无明显差异(P>0.05);2组治疗前SF-36各维度评分较无明显差异(P<0.05),治疗后,2组SF-36各维度评分较治疗前提高,治疗组高于对照组(P<0.05).结论 针对行结肠癌根治术患者术后给予中药健脾渗湿方联合化疗治疗疗效显著,有助于缓解患者临床症状,提高机体免疫功能,提升生活质量,从而改善远期预后,值得推广应用.     

胃溃疡不同中医证型和Hp感染相关性及辨证施治疗效研究

目的探讨胃溃疡不同中医证型和幽门杆菌(Hp)感染相关性及辨证施治疗效。方法选择2016年9月~2017年7月我院收治的胃溃疡患者100例,将所有患者根据随机数字表法分为两组。给予对照组50例常规西药治疗,在此基础上给予治疗组50例中医辨证治疗。比较两组Hp清除率、临床疗效、中医症候积分。结果对照组Hp根除率为82.00%低于观察组的96.00%,差异有统计学意义(P<0.05);对照组治疗总有效率为80.00%,观察组治疗总有效率为96.00%,差异有统计学意义(P<0.05);观察组中医症候积分为(3.61±1.26)分低于对照组的(8.62±2.13)分,差异有统计学意义(P<0.05)。结论中医辨证治疗胃溃疡临床疗效显著,能提高Hp根除率,改善患者临床症状。     

子午流注择时穴位贴敷治疗脾胃虚弱证妊娠恶阻的效果观察

目的 观察对脾胃虚弱证妊娠恶阻患者施以子午流注择时穴位贴敷的效果。方法 观察对象60例脾胃虚弱证妊娠恶阻患者，随机数字法施以分组，施以西医常规治疗的30例患者分入对照组，施以子午流注择时穴位贴敷治疗的30例患者分入研究组，对治疗效果进行对比和观察。结果 临床疗效研究组明显好（P<0.05）；治疗时间（尿酮体转阴、恶心呕吐消失、住院）研究组均明显短（P<0.05）；中医症候积分治疗前2组比较（P>0.05）；中医症候积分（饮食障碍、呕吐、恶心）研究组治疗后均明显低于对照组（P<0.05）；复发率研究组明显低于对照组（P<0.05）。结论 对脾胃虚弱证妊娠恶阻患者施以子午流注择时穴位贴敷效果良好，此治疗方法推广价值较高。     

疏肝健脾汤治疗肝郁脾虚型脾胃病治疗对患者胃黏膜修复及症状积分的影响

目的探究疏肝健脾汤治疗肝郁脾虚型脾胃病对患者胃黏膜修复情况及症状积分的影响。方法选择来我院就诊的122例肝郁脾虚型脾胃病患者,按照随机数字表法将患者分成2组,每组61例。对照组患者采用常规西药治疗,观察组患者接受疏肝健脾汤治疗。连续治疗4个疗程后,比较2组患者临床疗效、胃黏膜修复情况以及中医症状平均积分、幽门螺杆菌(Hp)清除率。结果治疗后,2组中医证候积分均较治疗前降低,其中观察组平均中医证候积分明显低于对照组;观察组临床治疗总有效率明显高于对照组,胃黏膜修复效果明显优于对照组,且Hp清除率明显高于对照组,上述差异均具有统计学意义(P<0.05)。结论疏肝健脾汤能更有效地改善肝郁脾虚型脾胃病患者临床症状,提高患者胃黏膜修复率与Hp清除率,疗效显著。     

调胃健脾汤加减治疗功能性消化不良的临床观察

目的探讨调胃健脾汤加减治疗功能性消化不良的临床效果。方法将90例功能性消化不良患者随机分为两组各45例,对照组接受常规西医治疗,研究组在西医治疗基础上加用调胃健脾汤加减治疗。比较两组治疗前后的主要症状积分和临床疗效。结果两组治疗后的脘腹胀满、嗳气呃逆、胃脘隐痛、纳差食少等主要症状积分均明显下降(P<0.05),且研究组明显低于对照组(P<0.05)。研究组总有效率97.8%,明显高于对照组86.7%(P<0.05)。结论调胃健脾汤加减治疗功能性消化不良具有确切的疗效。     

龙胆泻肝汤加减对肝火上炎型高血压患者血压、中医症候积分及生存质量的影响

目的探讨龙胆泻肝汤加减联合硝苯地平控释片对肝火上炎型高血压患者血压、中医症候积分及生存质量的影响。方法选择2016年10月～2019年9月于广东医科大学附属第二医院确诊的80例肝火上炎型高血压患者,按照随机数字表法分为对照组(n=40)和观察组(n=40),两组均给予硝苯地平控释片治疗,观察组在此基础上加用龙胆泻肝汤加减治疗,比较两组血压、中医症候积分、临床疗效及生存质量评分。结果与治疗前比较,治疗后观察组和对照组患者的收缩压、舒张压、中医症候积分均显著下降(P 0.05);治疗后观察组患者的收缩压、舒张压、中医症候积分均低于对照组,差异有统计学意义(P 0.05);观察组患者的高血压治疗总有效率显著高于对照组(92.50%vs. 75.00%),差异有统计学意义(P 0.05);治疗后观察组中医症候改善总有效率为95.00%,显著高于对照组的77.50%(P 0.05);治疗后观察组患者的躯体功能、总体健康、社会功能、精神健康、活力均明显高于对照组,差异有统计学意义(P 0.05)。结论龙胆泻肝汤加减联合硝苯地平控释片对肝火上炎型高血压临床疗效显著,有效降低血压、中医症候,提高生存质量。     

益气健脾法与糖皮质激素联合治疗原发性免疫性血小板减少症的临床效果观察

目的 探讨益气健脾法与糖皮质激素联合治疗原发性免疫性血小板减少症的临床效果。方法 68例原发性免疫性血小板减少症患者,根据治疗方法不同分为研究组和对照组,各34例。对照组单纯采取糖皮质激素治疗,研究组采取糖皮质激素联合益气健脾法治疗。比较两组的治疗效果及治疗前后中医症候积分和血小板计数。结果 研究组治疗总有效率97.06%高于对照组的76.47%,差异具有统计学意义(P<0.05)。治疗前,两组中医症候积分比较差异无统计学意义(P>0.05);治疗后,研究组患者的中医症候积分(4.98±0.11)分低于对照组的(12.72±1.32)分,差异具有统计学意义(P<0.05)。治疗前,两组血小板计数比较差异无统计学意义(P>0.05);治疗后,研究组患者的血小板计数(119.65±10.36)×109/L高于对照组的(84.36±8.69)×109/L,差异具有统计学意义(P<0.05)。结论 益气健脾法与糖皮质激素联合治疗原发性免疫性血小板减少症的临床效果更佳,可有效纠正患者血小板指标,并积极改善患者病情,值得借鉴。     

Effects of cannabidiol and of diphenylhydantoin on the hippocampus and on learning

Cannabidiol (3.5 mg/kg, i.p.) depressed hippocampal facilitation and posttetanic potentiation of evoked responses in rats, such, as had been reported before for diphenylhydantoin. Both diphenylhydantoin (80 mg/kg, i.p.) and cannabidiol blocked the increase of hippocampal RNA concentration caused by afferent stimulation, and depressed the acquisition of a conditioned avoidance response in rats. Neither drug affected the retention of such response when given by posttrial injection, nor the spontaneous locomotor activity of mice. The effects of both agents may be explained by the interference they have been previously shown to produce with the release of K⁺ from the hippocampus during stimulation. In fact, hippocampal facilitation and posttetanic potentiation and the RNA response to stimulation have been shown to be phenomena which depend on this K⁺ release, and have been attributed a role in learning.     

β3-肾上腺素受体激动剂的研究进展

摘要β     

妊娠合并子宫肌瘤对母儿影响的分析

目的 探讨妊娠合并子宫肌瘤对母儿的影响。方法 对1999年1月～2004年12月73例在剖宫产术中发现的子宫肌瘤进行分析。结果 妊娠合并肌瘤的胎位异常（臂位）率、产后出血率分别为17．8％、20．54％,而对照组分别为3．18％和8．97％;低体重儿发生率12、33％,而对照组为6．07％,有显著差异。结论 子宫肌瘤增加了母儿并发症的可能性;合并黏膜下肌瘤也有望使妊娠过程成功。     

朱砂及含朱砂制剂的肝肾毒性研究

目的 探讨朱砂、含朱砂制剂（柏子养心片）及甲基汞对大鼠的体内外毒性,为其临床安全用药提供科学依据。方法 ①对比甲基汞、朱砂及柏子养心片体外对人肝HL-7702细胞和人肾近曲小管上皮HK2细胞的毒性,计算半数抑制浓度（IC₅₀）。②SD大鼠随机分为对照组,朱砂组0.1 g/kg,柏子养心片0.2、0.4、0.8 g/kg组,甲基汞组0.001 g/kg,每天ig 1次,连续给药90 d后,取血及肝、肾组织;试剂盒法检测血清中丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、肌酐（CREA）、尿素氮（BUN）水平,测汞仪固体直接进样法检测肝、肾组织中汞蓄积量,并对大鼠肝脏和肾脏做组织病理学检查。结果 体外试验表明,朱砂、柏子养心片及甲基汞对HL-7702细胞的IC₅₀分别为7.852、6.035、0.009 5 g/L;对HK2细胞的IC₅₀分别为6.297、4.484、0.008 9 g/L。亚慢性毒性试验表明,甲基汞组大鼠肝、肾组织中汞蓄积量及血清中ALT、AST、CREA、BUN值均显著高于对照组,而朱砂及柏子养心片（高、中、低剂量）组与对照组比较均没有显著性差异;甲基汞组大鼠肝脏呈现肝细胞变性,肾脏可见明显肾小管损伤,而朱砂及柏子养心片（高、中、低剂量）组与对照比较没有明显差异。结论 朱砂及柏子养心片的体内外毒性均显著低于甲基汞,在目前药典规定的临床用量下使用安全性较好。     

Effects of raunescine and isoraunescine on behaviour and on the 5-hydroxytryptamine and noradrenaline contents of brain

Some behavioural effects of raunescine and isoraunescine on pigeons have been studied; no qualitative difference was detected between their effects and those of reserpine. Isoraunescine is between five and ten times less potent than raunescine, which, in turn, is much less potent than reserpine in producing these effects.

Both raunescine (5 mg./kg.) and isoraunescine (50 mg./kg.) were found to cause a reduction in the concentration of noradrenaline in the brains of rats. Raunescine (5 mg./kg.) also caused a reduction in the concentration of 5-hydroxytryptamine in brain; isoraunescine did not do so in the same dose; higher dose levels were not studied.

     

Influence of streptozotocin-induced diabetes on blood pressure and on renin formation and release

Summary I.v. injection of 40 mg/kg or 65 mg/kg streptozotocin reliably induced diabetes in female Sprague-Dawley rats, but failed to induce hypertension within the following 42 days. In most animals injected with the higher dose and in some animals injected with the lower dose, the tail blood flow was permanently impaired so that no blood pressure signals could be obtained by tail plethysmography. This phenomenon occurred also when the drug was injected into the jugular vein and thus was not due to a local effect of streptozotocin. 15 days after 65 mg/kg streptozotocin, the mean arterial pressure of the rats was similar to that of controls, when measured in the awake state (carotid cannula) or under ether anaesthesia. 42 days after streptozotocin, under pentobarbital anaesthesia, the blood pressure was again normal in the animals given 40 mg/kg of the drug and depressed in the animals given 65 mg/kg of the drug 42 days previously. The increase of blood pressure induced by 1 g/kg (–)-noradrenaline i.v. was similar in the latter group of animals and in controls.The renal cortical renin concentration was much lower than in controls 42 days after either dose of streptozotocin, while the plasma renin activity was normal (40 mg/kg) or increased (65 mg/kg). The low renal renin content may have been due to the diabetic state, rather than to the drug itself. Adrenal medullary dopamine-beta-hydroxylase activity was increased 42 days after the higher dose of streptozotocin.Supported by the Swiss National Science Foundation, grant Nr. 3.410.078     

Effect of endothelin on total and regional coronary resistance and on myocardial contractility

Endothelin is a 21-amino acid peptide produced by the endothelium and has a potent vasoconstrictor effect. Because of the importance of the endothelium on vasomotor regulation, we studied the effect of endothelin on total and regional coronary vascular resistance and on myocardial contractility in the intact heart of anesthetized dogs. Intracoronary administration of 2 to 80 pmol/kg of endothelin produced a dose-dependent increase in coronary resistance, ischaemic decrease in myocardial contractility and atrium-ventricular blockade. The increase in resistance was greater towards the outer layer of the left ventricular wall. When the coronaries were perfused at a constant rate and vasoconstriction was prevented with adenosine or nitroglycerine, endothelin did not produce inotropic changes. These results show that endothelin is a potent vasoconstrictor of the resistance coronary vessels, producing a redistribution of transmural blood flow and a decrease in myocardial contractility secondary to ischaemia.     

丹参多酚酸盐治疗不稳定型心绞痛的疗效及其对一氧化氮和内皮素的影响

目的观察丹参多酚酸盐治疗不稳定型心绞痛（UA）的疗效及其对血清一氧化氮（NO）和内皮素（ET）水平的影响。方法 60例患者随机分为治疗组和对照组各30例。对照组给予常规抗心绞痛治疗,治疗组在对照组治疗的基础上加用丹参多酚酸盐注射液。观察比较2组临床疗效、血清NO和ET水平及心电图改善和药物不良反应情况。结果 治疗组临床疗效、血清NO和ET水平及心电图改善情况均优于对照组,差异有统计学意义（P〈0.05）。2组均未发生药物不良反应。结论丹参多酚酸盐可明显改善UA患者的临床症状和心电图ST-T改变,要提高血清NO水平的同时降低ET水平。     

Effect of ranitidine on ileal myenteric plexus preparation and on acetyl- and butyrylcholinesterase

Ranitidine at concentrations from 1 microM to 0.1 mM brought about a dose-dependent potentiation of the twitch responses elicited by electrical stimulation of the ileal myenteric preparation. At higher concentrations (0.3-3 mM) ranitidine also caused irregular slow contractions of the unstimulated ileal preparation which were potentiated by eserine and blocked by atropine and tetrodotoxin. In order to identify the mechanism of these apparently cholinomimetic actions, the effects of ranitidine on AChE and BuChE were studied. Ranitidine showed an instantaneous and promptly reversible inhibitory action at concentrations between 0.5 and 30 microM. Double reciprocal plots were prepared and equilibrium dissociation constants calculated. It appears that ranitidine exerts an inhibition of the "mixed" type on both AChE and BuChE, but the dissociation constants for BuChE were markedly higher than those for AChE. Since AChE inhibition occurs in the same concentration range potentiating the twitch responses on the ileal myenteric preparation, it may explain the cholinomimetic effect of ranitidine.